Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akesis Pharmaceuticals names new CEO
Dr LeBel has served as president and COO since June 2008 and has been on Akesis’s board of directors since December 2007. The company has stated that the
Dr LeBel has served as president and COO since June 2008 and has been on Akesis’s board of directors since December 2007. The company has stated that the
Under the terms of the agreement, Replidyne will issue new shares of its common stock to Cardiovascular Systems (CSI) shareholders whereby former CSI shareholders are expected to own
The immediate release formulation of Sanvar, a somatostatin analogue, is used in the treatment of acute esophageal variceal bleeding. It is used prior to endoscopic intervention to control
Hospital procedures range from the use of bone chips, tendons and other tissues in surgeries, organ replacements, and marrow and stem cell transplantations in more advanced therapies. BiologiCare
The practice staffs the level III neonatal intensive care unit at North Oaks Medical Center, which has annual patient volume in excess of 3,500 patient days. Pediatrix has
Under the terms of the agreement, Osiris will commercialize Prochymal and Chondrogen in the US and Canada, and Genzyme will commercialize the treatments in all other countries. Genzyme
Source BioScience has appointed a number of distributors for its Geneservice life science research products in the important East Asian market. EnoGene Biotech has been appointed in China
In his new role, Dr Macdonald will be primarily responsible for developing new commercial opportunities for Sinclair with a particular focus on dermatology products. Dr Macdonald has over
Selectivity was tested by evaluating the interaction between tyramine and rasagiline in healthy subjects. This double blind placebo controlled study was conducted in order to comply with the
Anders Ekblom is appointed to the role of executive vice president of development, effective January 1, 2009, when he will also join AstraZeneca’s senior executive team. Mr Ekblom